Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2004-07-01 (21 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: METABIEF (25370), Doubs
PHARMACIE DU BIEF ROUGE : revenue, balance sheet and financial ratios
PHARMACIE DU BIEF ROUGE is a French company
founded 21 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in METABIEF (25370),
this company of category PME
shows in 2025 a revenue of 1.9 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DU BIEF ROUGE (SIREN 477747331)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
1 928 101 €
1 783 428 €
1 798 319 €
2 143 682 €
1 626 261 €
1 547 056 €
1 588 732 €
1 568 156 €
1 530 361 €
1 492 288 €
Net income
116 352 €
125 993 €
148 326 €
269 358 €
213 302 €
146 650 €
96 999 €
209 784 €
202 935 €
481 757 €
EBITDA
96 508 €
104 725 €
133 049 €
357 538 €
147 153 €
137 022 €
108 342 €
154 018 €
91 293 €
121 604 €
Net margin
6.0%
7.1%
8.2%
12.6%
13.1%
9.5%
6.1%
13.4%
13.3%
32.3%
Revenue and income statement
In 2025, PHARMACIE DU BIEF ROUGE achieves revenue of 1.9 M€. Revenue is growing positively over 10 years (CAGR: +2.9%). Vs 2024: +8%. After deducting consumption (1.4 M€), gross margin stands at 578 k€, i.e. a rate of 30%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 97 k€, representing 5.0% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 116 k€, i.e. 6.0% of revenue. This profit can be retained or distributed to shareholders.
Revenue (2025)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
1 928 101 €
Gross margin (2025)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
578 003 €
EBITDA (2025)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
96 508 €
EBIT (2025)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
80 701 €
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
116 352 €
EBITDA margin (2025)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
5.0%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 16%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 77%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 2.5 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 5.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
16.094%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
77.04%
Cash flow / Revenue (2025)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
5.734%
Repayment capacity (2025)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
2.454
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DU BIEF ROUGE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
20.041
54.027
43.691
38.524
37.943
29.034
21.511
26.231
23.882
16.094
Financial autonomy
71.359
59.306
62.915
64.28
68.262
71.931
76.19
71.175
72.009
77.04
Repayment capacity
0.745
4.42
3.862
11.427
6.387
2.328
1.974
2.963
3.175
2.454
Cash flow / Revenue
24.264%
12.37%
11.677%
3.641%
7.152%
15.921%
11.817%
7.992%
6.619%
5.734%
Sector positioning
Debt ratio
16.092025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good
In 2025, the debt ratio of PHARMACIE DU BIEF ROUGE (16.09) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
77.04%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Excellent
In 2025, the financial autonomy of PHARMACIE DU BIEF ROUGE (77.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
2.45 years2025
2023
2024
2025
Q1: 0.51 years
Med: 2.46 years
Q3: 6.17 years
Good+6 pts over 3 years
In 2025, the repayment capacity of PHARMACIE DU BIEF ROUGE (2.45) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 331.94. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 7.0x. Operating income very largely covers interest expenses: high safety margin.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
331.943
Interest coverage (2025)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable 1.5-3 : Acceptable < 1.5 : Risk
6.985
Liquidity indicators evolution PHARMACIE DU BIEF ROUGE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
404.4
536.281
476.466
433.921
829.026
714.789
706.205
358.685
316.819
331.943
Interest coverage
8.676
13.017
6.66
7.859
5.722
4.431
1.767
4.861
7.161
6.985
Sector positioning
Liquidity ratio
331.942025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Excellent
In 2025, the liquidity ratio of PHARMACIE DU BIEF ROUGE (331.94) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
6.99x2025
2023
2024
2025
Q1: 0.0x
Med: 1.91x
Q3: 5.98x
Excellent+11 pts over 3 years
In 2025, the interest coverage of PHARMACIE DU BIEF ROUGE (7.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 5 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 42 days. Excellent situation: suppliers finance 37 days of the operating cycle (retail model). Inventory turnover is 35 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 127 days of revenue, i.e. 678 k€ to permanently finance. Over 2016-2025, WCR increased by +33%, requiring additional financing.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
678 422 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
5 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
42 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
35 j
WCR in days of revenue (2025)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
127 j
WCR and payment terms evolution PHARMACIE DU BIEF ROUGE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
510 437 €
663 289 €
956 230 €
1 042 256 €
1 139 484 €
1 186 211 €
1 282 136 €
628 872 €
645 744 €
678 422 €
Inventory turnover (days)
36
36
44
39
38
33
31
40
46
35
Customer payment term (days)
12
14
16
14
8
9
8
5
4
5
Supplier payment term (days)
65
52
53
52
35
38
32
46
47
42
Positioning of PHARMACIE DU BIEF ROUGE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE DU BIEF ROUGE is estimated at
1 093 198 €
(range 697 311€ - 1 527 237€).
With an EBITDA of 96 508€, the sector multiple of 7.7x is applied.
The price/revenue ratio is 0.61x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
697k€1093k€1527k€
1 093 198 €Range: 697 311€ - 1 527 237€
NAF 5 année 2025
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
96 508 €×7.7x
Estimation745 071 €
375 736€ - 1 084 668€
Revenue Multiple30%
1 928 101 €×0.61x
Estimation1 170 033 €
861 983€ - 1 349 558€
Net Income Multiple20%
116 352 €×15.9x
Estimation1 848 265 €
1 254 242€ - 2 900 183€
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DU BIEF ROUGE with other companies in the same sector:
Frequently asked questions about PHARMACIE DU BIEF ROUGE
What is the revenue of PHARMACIE DU BIEF ROUGE ?
The revenue of PHARMACIE DU BIEF ROUGE in 2025 is 1.9 M€.
Is PHARMACIE DU BIEF ROUGE profitable?
Yes, PHARMACIE DU BIEF ROUGE generated a net profit of 116 k€ in 2025.
Where is the headquarters of PHARMACIE DU BIEF ROUGE ?
The headquarters of PHARMACIE DU BIEF ROUGE is located in METABIEF (25370), in the department Doubs.
Where to find the tax return of PHARMACIE DU BIEF ROUGE ?
The tax return of PHARMACIE DU BIEF ROUGE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DU BIEF ROUGE operate?
PHARMACIE DU BIEF ROUGE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart